iCast™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients with Resistant Hypertension
Principle Investigator: Dr. Michael Miller
What is the purpose of the study?
The primary objective of the ARTISAN trial is to evaluate the safety and efficacy of the iCAST™ RX Stent System for the treatment of subjects with resistant hypertension associated with de novo atherosclerotic renal artery disease.
Who is eligible?
Patients who are candidates for a renal artery revascularization with > 80% visual stenosis and have resistant hypertension with > 155 mmHg while on > anti-hypertensive medications from at least 3 distinct classes of drugs. The patient must meet all inclusion and none of the exclusion criteria required by the study.
For more information, contact:
Dr. Michael Miller
Link to the current ClinicalTrials.gov record »